Final Updated on March 10, 2022 by GlobeNewsWire
SHANGHAI and PRINCETON, N.J., March 10, 2022 (World NEWSWIRE) Pursuing the Determination Report of the Public Firm Accounting Oversight Board (PCAOB) issued on December 16, 2021, on March 8, 2022 the U.S. Securities and Exchange Commission (the SEC) launched a provisional record of corporations recognized as Commission-Discovered Issuers less than the Keeping Overseas Providers Accountable Act (HFCAA). LianBio (Nasdaq: LIAN) is not currently on this listing and does not expect to be named by the SEC as a Commission Determined Issuer underneath the HFCAA.
Not like the firms now identified on the SECs provision list, LianBios retained principal auditor is a significant independent public accounting business positioned in New York, United states and is at present inspected by the PCAOB. Thus, LianBio does not believe that it will be matter to the provisions less than the HFCAA that are relevant to issuers whose auditors are found in a overseas jurisdiction and that the PCAOB is unable to examine or examine.
Significant data and disclosures on these topics contained in LianBios community filings are obtainable on its internet site and at www.sec.gov.
About LianBio
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. By partnerships with very progressive biopharmaceutical providers all over the entire world, LianBio is advancing a diversified portfolio of clinically validated solution candidates with the possible to travel new standards of care throughout cardiovascular, oncology, ophthalmology, inflammatory condition and respiratory indications. LianBio is creating an international infrastructure to placement the business as a spouse of alternative with a platform to supply obtain to China and other Asian marketplaces. For more info, be sure to pay a visit to www.lianbio.com
For media inquiries, remember to get in touch with:
[email protected]
For trader inquiries, please contact:
[email protected]
